Bearish
Palantir's stock drops 6% amid valuation concerns and NHS contract scrutiny
Palantir Technologies' stock declined by 6.1% to $124.57 on July 23, 2026, as investors expressed caution ahead of the company's second-quarter earnings report. Concerns over the company's high valuation and ongoing scrutiny of its UK National Health Service (NHS) contract contributed to the selloff. The upcoming earnings report on August 3 is critical for Palantir to maintain investor confidence and justify its premium valuation.
Key points
- Palantir's stock drops 6% amid valuation concerns and NHS contract scrutiny
- Palantir's upcoming earnings report on August 3 is critical for investor confidence
Sources
AI-generated from public news sources. Not financial advice.
